Table 5.
Participant outcomes observed longitudinally
| Variable | BL (N = 27) | 4MFU (N = 24) | 8MFU (N = 23) |
|---|---|---|---|
| Viral load | |||
| Log PVL M(SD) | 4.06 (1.04) | 2.49 (2.14) | 2.77 (2.12) |
| Undetectable (< 200) Frequency (%) | 1 (3.7%) | 12 (50%) | 8 (36.4%) |
| PVL Not Available Frequency (%) | 0 (0%) | 0 (0%) | 1 (4.5%) |
| Self-report adherence | |||
| Percent prior 2 weeks M(SD) | 68.1 (31.99) | 81.7 (28.39) | 85.7 (23.71) |
| Wisepill adherence | |||
| Percent prior weeka M(SD) | 68.75 (33.36) | 74.06 (31.15) | 47.06 (46.23) |
| PHQ-9 depression | |||
| M(SD) | 6.12 (6.56) | 3.68 (4.43) | 4.08 (4.54) |
| PANAS: positive affect | |||
| M(SD) | 31.76 (10.71) | 35.08 (10.16) | 35.86 (10.65) |
| Missing F(%) | 2 (7.4%) | 0 (0%) | 1 (4.5%) |
| PANAS: negative affect | |||
| M(SD) | 17.74 (7.84) | 13.38 (4.02) | 16.91 (8.91) |
| Missing F(%) | 4 (14.81%) | 0 (0%) | 0 (0%) |
a
Average percent adherence is presented for the week following the baseline visit, the 16th week (approximation of 4 months from baseline), and the 32nd week (approximation of 8 months from baseline)